Neurocrine Biosciences
NBIX
#1552
Rank
A$17.96 B
Marketcap
$180.14
Share price
0.26%
Change (1 day)
-11.21%
Change (1 year)
Neurocrine Biosciences is an American biopharmaceutical company that develops treatments for neurological and endocrine-related diseases and disorders.

EPS for Neurocrine Biosciences (NBIX)

EPS in 2023 (TTM): $2.98

According to Neurocrine Biosciences 's latest financial reports the company's current EPS (TTM) is $3.09. In 2022 the company made an earnings per share (EPS) of $2.54 an increase over its 2021 EPS that were of $1.50.

EPS history for Neurocrine Biosciences from 1997 to 2023

Annual EPS

Year EPS Change
2023 (TTM)$2.9817.35%
2022$2.5469.47%
2021$1.50-78.21%
2020$6.87990%
2019$0.6381.82%
2018$0.35-113.5%
2017-$2.570.62%
2016-$2.5557.28%
2015-$1.6225.61%
2014-$1.2918.84%
2013-$1.09-1085.71%
2012$0.11-89.71%
2011$1.07-500%
2010-$0.27-86.92%
2009-$2.05-43.48%
2008-$3.63-57.8%
2007-$8.5992.58%
2006-$4.46371.67%
2005-$0.95-52.76%
2004-$2.0036.56%
2003-$1.47-70%
2002-$4.89118.31%
2001-$2.248.4%
2000-$2.0748.86%
1999-$1.39-20%
1998-$1.73-479.31%
1997$0.46

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
$3.29 6.63%๐Ÿ‡บ๐Ÿ‡ธ USA
$0.87-71.94%๐Ÿ‡ฌ๐Ÿ‡ง UK
-$4.67-251.02%๐Ÿ‡บ๐Ÿ‡ธ USA
$8.56 177.00%๐Ÿ‡บ๐Ÿ‡ธ USA
$5.80 87.79%๐Ÿ‡บ๐Ÿ‡ธ USA
$2.93-5.10%๐Ÿ‡บ๐Ÿ‡ธ USA
-$0.74-123.98%๐Ÿ‡บ๐Ÿ‡ธ USA
-$4.78-254.59%๐Ÿ‡บ๐Ÿ‡ธ USA